PSY-007

PSY-007 is a small molecule NMDA receptor antagonist being developed by Psycheceutical Bioscience for the treatment of Post-Traumatic Stress Disorder (PTSD) and Complex Regional Pain Syndrome (CRPS). The drug is a patented topical formulation of ketamine that utilizes the company's proprietary NeuroDirect delivery technology. This platform is designed to deliver the medication topically to the sub-occipital region (the back of the neck), aiming to transport the active ingredient directly to the nervous system while bypassing the blood-brain barrier and systemic circulation. By targeting the nervous system directly, PSY-007 is intended to provide rapid therapeutic relief while minimizing the systemic exposure and dissociative side effects typically associated with traditional ketamine administration. PSY-007 is currently in Phase 1 clinical development for PTSD and in preclinical stages for CRPS.

Other names

NeuroDirect Ketamine